NCT06422247View on ClinicalTrials.gov

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

CompletedOBSERVATIONAL
Enrollment

307

Participants

Timeline

Start Date

April 5, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Systemic therapy

Approved peripheral T-cell lymphoma systemic treatments prescribed by the treating physician

Trial Locations (1)

105-0001

Mebix, Inc, Minato-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06422247 - Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | Biotech Hunter | Biotech Hunter